ECASS

MIVI Neuroscience™ Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference

Retrieved on: 
Thursday, February 8, 2024
Technology, Radiology, Health Technology, Pharmaceutical, Neurology, Other Science, Research, Medical Devices, Infectious Diseases, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Practice Management, General Health, Nanotechnology, Science, Medical Supplies, Software, FDA, Surgery, Other Health, Sich, CE marking, Cerebrovascular disease, LVO, NIHSS, Conference, Bangladesh Technical Education Board, Intracranial hemorrhage, Thrombectomy, Safety, Physician, ECASS, Reperfusion, IDE, Thrombus, Patient, Stroke, System, Death

MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.

Key Points: 
  • MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.
  • The data were presented yesterday at the 2024 International Stroke Conference (AZ), a premier event featuring global thought leaders and dedicated to the latest in the science and treatment of cerebrovascular disease and brain health.
  • Results of the EvaQ Trial show the Q Revascularization System to be safe and effective for thrombectomy of Large Vessel Occlusion (LVO) strokes.
  • The primary safety endpoint was symptomatic intracranial hemorrhage (sICH) which was observed at a rate of 6.5%.

Smidge Small Batch Supplements® launches grass-fed, Australian Emu Oil for real food vitamin K2

Retrieved on: 
Monday, October 9, 2023
Famine, Parent, Nutrient, MK-7, Emu oil, Vitamin K, Allergen, Oil, K2, Collagen, Skin, Grandiosity, Athlete, Sustainability, Vitamin K2, Dietary supplement, Animal husbandry, Food preservation, ECASS

Emu Oil has naturally occurring vitamin K2 (MK-4) — 1,500 mg of 100% Emu Oil with no fillers, additives or common allergens

Key Points: 
  • Emu Oil has naturally occurring vitamin K2 (MK-4) — 1,500 mg of 100% Emu Oil with no fillers, additives or common allergens
    Sustainably sourced from grass-fed, heritage-bred Australian emus to support collagen production and skin, bone and dental health*
    Provides the most bioavailable and absorbable form of vitamin K2, which is MK-4
    Gentle, prompt, low-heat rendering process retains all of the oil's nutritional properties and cofactors for fresh, high-quality Emu Oil
    SOUTHFIELD, Mich., Oct. 9, 2023 /PRNewswire/ -- Smidge® has recently added a new small-batch supplement to their premium, clean line product line that offers essential nutrients lacking in even the best whole foods diets:
    Smidge Small Batch Supplements® launches grass-fed, Australian Emu Oil for real food vitamin K2, as MK-4
    Emu Oil for real food vitamin K2, as MK-4.
  • And they contain a synergistic combination of unadulterated, natural nutrients — especially vitamin K2 (MK-4) and omega fatty acids (3,6,7 and 9).
  • Each serving contains 1,500 mg of 100% pure Smidge® Emu Oil, including 6.4 mcg of vitamin K2 (MK-4).
  • "The best part is the vitamin K2 in our Emu Oil doesn't require conversion like other forms of vitamin K (such as MK-7, the plant form).